{"id":56545,"date":"2026-02-06T22:18:50","date_gmt":"2026-02-06T14:18:50","guid":{"rendered":"https:\/\/flcube.com\/?p=56545"},"modified":"2026-02-06T22:18:51","modified_gmt":"2026-02-06T14:18:51","slug":"hengrui-pharma-secures-nmpa-nod-for-shr-1894-atopic-dermatitis-trial","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56545","title":{"rendered":"Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial"},"content":{"rendered":"\n<p><strong>Jiangsu Hengrui Pharmaceuticals Co., Ltd.<\/strong> (<strong><a href=\"https:\/\/www.google.com\/finance\/quote\/600276:SHA\">SHA: 600276<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/1276:HKG\">HKG: 1276<\/a><\/strong>), one of China\u2019s largest pharmaceutical companies, announced that the <strong>National Medical Products Administration (NMPA)<\/strong> has approved the initiation of a <strong>clinical study for SHR-1894<\/strong>, an in\u2011house developed therapeutic biologic targeting <strong>atopic dermatitis (AD)<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Jiangsu Hengrui Pharmaceuticals (SHA: 600276, HKG: 1276)<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Asset<\/strong><\/td><td>SHR-1894 (therapeutic biologic)<\/td><\/tr><tr><td><strong>Approval<\/strong><\/td><td>Clinical trial authorization<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Atopic dermatitis (AD)<\/td><\/tr><tr><td><strong>Development Status<\/strong><\/td><td>In\u2011house developed; early\u2011stage clinical<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Class:<\/strong> Novel therapeutic biologic<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Dual\u2011action approach anticipated to:<\/li>\n\n\n\n<li><strong>Protect skin barrier integrity<\/strong> \u2013 Addressing structural defects in AD pathophysiology<\/li>\n\n\n\n<li><strong>Inhibit inflammation<\/strong> \u2013 Targeting underlying immune dysregulation driving disease flares<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> Positioned as a next\u2011generation biologic potentially offering <strong>barrier repair + immunomodulation<\/strong> in a single agent, distinct from existing IL\u20114\/IL\u201113 or JAK\u2011targeted therapies<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-strategic-positioning\">Market Context &amp; Strategic Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>AD Market Scale:<\/strong> China\u2019s atopic dermatitis therapeutics market is projected to exceed <strong>$3 billion by 2030<\/strong>, driven by underdiagnosis correction and biologic adoption in moderate\u2011to\u2011severe patients.<\/li>\n\n\n\n<li><strong>Hengrui\u2019s Biologic Push:<\/strong> SHR-1894 advances Hengrui\u2019s <strong>strategic pivot from generics to innovative biologics<\/strong>, complementing its established oncology portfolio with high\u2011value immunology assets.<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> Entry into AD positions Hengrui against <strong>dupilumab (Sanofi\/Regeneron)<\/strong> and emerging Chinese biosimilars\/biologics; SHR-1894\u2019s novel mechanism may enable differentiation if clinical data supports superior skin barrier outcomes.<\/li>\n\n\n\n<li><strong>Dual\u2011Listing Advantage:<\/strong> Shanghai\/Hong Kong listings provide <strong>domestic RMB funding and international investor access<\/strong>, supporting parallel development of SHR-1894 and broader immunology pipeline.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-roadmap\">Development Roadmap<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Phase<\/th><th>Activity<\/th><th>Timeline<\/th><\/tr><\/thead><tbody><tr><td><strong>Current<\/strong><\/td><td>Phase I clinical trial initiation (NMPA approved)<\/td><td>Q1 2026<\/td><\/tr><tr><td><strong>Next<\/strong><\/td><td>Proof\u2011of\u2011concept data in AD patients<\/td><td>2026\u20112027<\/td><\/tr><tr><td><strong>Future<\/strong><\/td><td>Phase II dose\u2011optimization and registrational planning<\/td><td>Data\u2011dependent<\/td><\/tr><tr><td><strong>Strategic<\/strong><\/td><td>Potential combination studies with Hengrui\u2019s JAK inhibitors<\/td><td>Pipeline synergy exploration<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding SHR-1894 clinical development, atopic dermatitis market positioning, and Hengrui Pharmaceuticals\u2019 biologics strategy. Actual results may differ due to early\u2011stage trial risks, competitive dynamics in the dermatology space, and regulatory requirements for AD drug approval.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/600276_20260206_XPQ4.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 600276_20260206_XPQ4.\"><\/object><a id=\"wp-block-file--media-f0d3e543-c126-4b90-9c88-616fd20a266f\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/600276_20260206_XPQ4.pdf\">600276_20260206_XPQ4<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/600276_20260206_XPQ4.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-f0d3e543-c126-4b90-9c88-616fd20a266f\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276), one of China\u2019s largest pharmaceutical companies,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[65,62,2586,4228,852],"class_list":["post-56545","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-auto-immune","tag-clinical-trial-approval-initiation","tag-hengrui-pharmaceuticals","tag-hkg-1276","tag-sha-600276"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276), one of China\u2019s largest pharmaceutical companies, announced that the National Medical Products Administration (NMPA) has approved the initiation of a clinical study for SHR-1894, an in\u2011house developed therapeutic biologic targeting atopic dermatitis (AD).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56545\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial\" \/>\n<meta property=\"og:description\" content=\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276), one of China\u2019s largest pharmaceutical companies, announced that the National Medical Products Administration (NMPA) has approved the initiation of a clinical study for SHR-1894, an in\u2011house developed therapeutic biologic targeting atopic dermatitis (AD).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56545\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-06T14:18:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-06T14:18:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56545#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56545\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial\",\"datePublished\":\"2026-02-06T14:18:50+00:00\",\"dateModified\":\"2026-02-06T14:18:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56545\"},\"wordCount\":352,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Auto-immune\",\"Clinical trial approval \\\/ initiation\",\"Hengrui Pharmaceuticals\",\"HKG: 1276\",\"SHA: 600276\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56545#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56545\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56545\",\"name\":\"Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-02-06T14:18:50+00:00\",\"dateModified\":\"2026-02-06T14:18:51+00:00\",\"description\":\"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276), one of China\u2019s largest pharmaceutical companies, announced that the National Medical Products Administration (NMPA) has approved the initiation of a clinical study for SHR-1894, an in\u2011house developed therapeutic biologic targeting atopic dermatitis (AD).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56545#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56545\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56545#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial - Insight, China&#039;s Pharmaceutical Industry","description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276), one of China\u2019s largest pharmaceutical companies, announced that the National Medical Products Administration (NMPA) has approved the initiation of a clinical study for SHR-1894, an in\u2011house developed therapeutic biologic targeting atopic dermatitis (AD).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56545","og_locale":"en_US","og_type":"article","og_title":"Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial","og_description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276), one of China\u2019s largest pharmaceutical companies, announced that the National Medical Products Administration (NMPA) has approved the initiation of a clinical study for SHR-1894, an in\u2011house developed therapeutic biologic targeting atopic dermatitis (AD).","og_url":"https:\/\/flcube.com\/?p=56545","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-06T14:18:50+00:00","article_modified_time":"2026-02-06T14:18:51+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56545#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56545"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial","datePublished":"2026-02-06T14:18:50+00:00","dateModified":"2026-02-06T14:18:51+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56545"},"wordCount":352,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Auto-immune","Clinical trial approval \/ initiation","Hengrui Pharmaceuticals","HKG: 1276","SHA: 600276"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56545#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56545","url":"https:\/\/flcube.com\/?p=56545","name":"Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-02-06T14:18:50+00:00","dateModified":"2026-02-06T14:18:51+00:00","description":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276), one of China\u2019s largest pharmaceutical companies, announced that the National Medical Products Administration (NMPA) has approved the initiation of a clinical study for SHR-1894, an in\u2011house developed therapeutic biologic targeting atopic dermatitis (AD).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56545#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56545"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56545#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hengrui Pharma Secures NMPA Nod for SHR-1894 Atopic Dermatitis Trial"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56545","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56545"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56545\/revisions"}],"predecessor-version":[{"id":56549,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56545\/revisions\/56549"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56545"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56545"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56545"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}